.png)
TL;DRManufacturer rebate (Herstellerabschlag) is a statutory rebate that pharmaceutical companies must grant the statutory health insurance funds (gesetzliche Krankenkassen, GKV) on the medicines dispensed at the funds' expense, governed by §130a SGB V. It is a rebate imposed by law, not one that is negotiated.
The mechanics sit in §130a Abs. 1 SGB V. The pharmacy deducts the rebate from the invoice it sends the fund, and the pharmaceutical company is then obliged to reimburse the pharmacy, or the wholesaler where one is designated under Abs. 5, within ten days of the claim. So the fund receives the money, the pharmacy fronts it on the invoice, and the manufacturer ultimately bears it. This is the core distinction from a Rabattvertrag, which is a confidential rebate negotiated between a single fund and a single manufacturer under §130a Abs. 8 SGB V.
The manufacturer rebate is an umbrella term for several statutory deductions that can apply to the same pack at the same time. The percentages below are verified verbatim against the current §130a SGB V text at gesetze-im-internet.de. Because these figures change with each cost-containment law, always confirm the live value at the statute before quoting it.
| Component | Legal basis | Rate / mechanism | Applies to |
|---|---|---|---|
| General rebate (Grundabschlag) | §130a Abs. 1 | 7% of the Abgabepreis des pharmazeutischen Unternehmers (APU) ex-VAT; 6% for the generic products defined in Abs. 3b Satz 1 | Finished medicines priced under the AMPreisV, not medicines with a Festbetrag (excluded by Abs. 3) |
| Generic rebate (Generikaabschlag) | §130a Abs. 3b | 10% of the APU ex-VAT | Patent-free, active-ingredient-identical medicines (patentfreie, wirkstoffgleiche Arzneimittel); waived where the APU is at least 30% below the Festbetrag |
| Price moratorium (Preismoratorium) | §130a Abs. 3a | A rebate equal to any price increase over the 1 August 2009 price level, running from 1 August 2010 to 31 December 2026 | All affected medicines, not those with a Festbetrag |
| Negotiated rebate (Rabattvertrag) | §130a Abs. 8 | Confidential, contract-specific, target term two years | Products a fund and a manufacturer agree individually; see Rabattvertrag |
The components stack. A patent-free generic can carry the reduced 6% general rebate under Abs. 1 and the 10% Generikaabschlag under Abs. 3b together, subject to the Festbetrag-related exemptions, while a price increase over the 2009 baseline additionally triggers the moratorium rebate. Medicines with a Festbetrag are exempt from the Abs. 1, 1a, 1b and 2 rebates entirely under Abs. 3.
These three instruments all reduce what the GKV pays, but they are not the same lever, and customer conversations often blur them.
The settlement path is defined in §130a Abs. 1 SGB V and runs in a fixed order.
The economic burden therefore lands on the pharmaceutical company, even though the money first moves through the pharmacy invoice. For a manufacturer, the sum of these statutory rebates is a direct deduction from net revenue on every GKV pack.
The Preismoratorium in §130a Abs. 3a SGB V freezes the reference price level at 1 August 2009. Where a manufacturer raises the APU above that 2009 level, the funds receive a rebate equal to the amount of the increase, so the higher price does not reach the GKV. The moratorium currently runs to 31 December 2026. To stop the freeze eroding through inflation, the statute raises the 2009 reference level once a year: first on 1 July 2018 and on 1 July of each following year, by the change in the consumer price index (Verbraucherpreisindex) published by the Statistisches Bundesamt. Festbetrag medicines are exempt.
The statutory rebate components reach the platform through the licensed ABDA article master data and surface in the price block of the article detail page. The header shows the price cascade at a glance, for example APU | EK | VK | FB | RAB, and RAB is the summed rebate value.
One honest limitation: pharmazie.com consolidates the §130a rebate fields as licensed article master data, it does not calculate a manufacturer's rebate liability for a specific fund. The confidential Rabattvertrag value under Abs. 8 is by law not public, so the platform can flag that a rebate contract exists but cannot show its amount. For a binding reimbursement figure, verify against the fund's own settlement.
